The manufacturer owns every word. A zenrep is built for exactly that.
FDA does not pre-approve promotional communication. The sponsor owns every sentence a rep says, the Office of Prescription Drug Promotion reads it after the fact, and the two most-enforced failures — overstated efficacy and omitted risk — are exactly the ones a conversation drifts into under pressure. Zenreps is built for that regime: control over what gets said, and a record of what was said.
- FDA — Office of Prescription Drug Promotion (OPDP)
- Federal Trade Commission (FTC)
- HHS Office of Inspector General (Anti-Kickback Statute)
What the regulator requires
Nine requirements govern promotional communication to US clinicians. They are the specification the US ruleset enforces.
- Truthful and non-misleading, by regulation.
- Prescription-drug promotion is governed by 21 CFR 202.1 under the FD&C Act. A false or misleading presentation is a per-se violation — a legal problem, not a tone problem.
- Approved claims only.
- An advertisement may not recommend or suggest any use that is not in the approved labeling, and may not claim greater efficacy or safety than substantial evidence demonstrates.
- Fair balance is the operative legal standard.
- Effectiveness may not be presented in greater scope, depth, or detail than risk information. Fair balance is a requirement of the regulation, not a courtesy.
- No off-label promotion, anywhere.
- Promoting an unapproved use is misbranding, with criminal and False Claims Act exposure. An off-label question may be answered only through a medical-information channel: private, individualized, balanced, handled by personnel independent of sales and marketing, with the request and the response recorded.
- No pre-clearance — every word is enforceable.
- FDA does not pre-approve promotional material. Sponsors file at first dissemination, FDA actively monitors promotional communications, and enforcement comes after the fact. Every promotional communication is enforceable promotional material from the moment it is sent.
- Promotion and scientific exchange stay separate.
- Scientific communication about unapproved uses must be kept separate and distinct from promotional communication, with the required disclosures. The two lanes never blend.
- Adverse events must be captured from any source.
- A serious, unexpected adverse event must reach FDA within 15 calendar days of the sponsor's receipt, and adverse-event records — including raw data — are kept for ten years. The duty attaches to every conversation, not just safety calls.
- Honest AI identity.
- Presenting an AI as human is a deception risk under FTC law, state AI-disclosure laws add proactive-disclosure duties for healthcare AI interactions, and impersonating a real person is separately prohibited.
- No inducements to prescribers.
- The Anti-Kickback Statute makes remuneration intended to induce prescribing a felony — and a single improper purpose is enough to taint an arrangement.
How the receipt answers the regulator
On the gated text channels — web chat and Telegram — every reply ships with the four-check receipt: in scope, grounded in approved material, fair-balanced, audit-recorded. Here is what each check holds, in OPDP terms.
Off-label asks are declined in the promotional conversation and routed to the medical-information channel; the promotional and scientific lanes never blend. (Requirements 4 and 6.)
Every claim traces to the sponsor's approved material; nothing beyond the label ships. (Requirements 1–2.)
Risk context is paired with every benefit claim, automatically — a benefit never travels alone. (Requirement 3.)
Every conversation produces a reviewable record — in a post-hoc enforcement regime, the record is the defense. Adverse-event mentions are captured and forwarded to your safety process in time for the 15-day clock. (Requirements 5 and 7.)
A zenrep discloses that it is AI at the start of the conversation — proactive disclosure, not disclosure-on-demand. And it offers no gifts, payments, or anything of value to a prescriber: it has nothing to give but approved information. (Requirements 8–9.)